NCT02555306View on ClinicalTrials.gov

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 16, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

0.5 mg of DE-122

DE-122 Injectable Solution

DRUG

1.0 mg of DE-122

DE-122 Injectable Solution

DRUG

2.0 mg of DE-122

DE-122 Injectable Solution

DRUG

4.0 mg of DE-122

DE-122 Injectable Solution

Trial Locations (5)

49202

Jackson

78503

McAllen

78705

Austin

94040

Mountain View

94598

Walnut Creek

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter